HC Wainwright Reiterates “Buy” Rating for IN8bio (NASDAQ:INAB)

HC Wainwright reaffirmed their buy rating on shares of IN8bio (NASDAQ:INAB) in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a $8.00 price objective on the stock.

IN8bio Stock Performance

Shares of INAB opened at $0.29 on Wednesday. IN8bio has a 12-month low of $0.22 and a 12-month high of $1.74. The business has a 50-day simple moving average of $0.28 and a two-hundred day simple moving average of $0.36. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05.

IN8bio (NASDAQ:INAB) last issued its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, analysts predict that IN8bio will post -0.56 EPS for the current year.

Institutional Investors Weigh In On IN8bio

Institutional investors have recently made changes to their positions in the stock. Sigma Planning Corp boosted its position in shares of IN8bio by 42.0% during the 3rd quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock valued at $230,000 after purchasing an additional 251,600 shares in the last quarter. Geode Capital Management LLC increased its position in shares of IN8bio by 56.5% during the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after acquiring an additional 185,919 shares during the last quarter. Franklin Resources Inc. purchased a new stake in shares of IN8bio during the fourth quarter valued at approximately $1,465,000. AIGH Capital Management LLC increased its position in IN8bio by 269.7% in the fourth quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock worth $1,593,000 after buying an additional 4,517,227 shares during the last quarter. Finally, BIOS Capital Management LP purchased a new stake in IN8bio in the fourth quarter worth $2,212,000. Institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.